BCL2 and myeloid leukemia: Studies in, for example, myeloid leukaemia, carcinoma of prostate and large cell Non Hodgkins lymphoma, have found bcl-2 expression to be associated with a poor response to treatment, and a shorter disease free and overall survival (Colombel, 1993; Reed et al, 1996).